Interestingly, analysis of 594 TCGA ER+ breast cancer samples showed CPT1A amplification and/or mRNA upregulation in 20% (117/594) of the ER+ breast cancer samples (Fig. 4e). This evidence concerns the gene CPT1A and breast carcinoma.